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Utility of Adaptive Strategy and Adaptive
Design for Biomarker-facilitated Patient
Selection in Pharmacogenomic or
Pharmacogenetic Clinical Development
Program
Sue-Jane Wang*
In the early to late phases of conventional clinical trials, improvement of disease status at study baseline is
the anchor of an effective treatment measured by therapeutic response. These population-based clinical
trials do not formally account for disease-associated marker genotype or genome-associated therapeutic
response. We discuss alternative study designs in pharmacogenomic or pharmacogenetic clinical trials for
genomic or genetic biomarker development, and for formally assessing the clinical utility of genomic or
genetic (composite) biomarkers. A two-stage adaptive strategy from completed, ongoing or prospectively
planned pharmacogenomic or pharmacogenetic clinical trials is described for development of a genomic
or genetic biomarker. We present two types of adaptive design: (1) the genomic biomarker is developed
external to the clinical trial, which is designed for treatment effect inference; and (2) first-stage data are used
to explore a genomic biomarker, but statistical inference of treatment effect in the genomically or genetically
defined biomarker subset is only performed at the second stage of the same trial. When the null hypothesis
of no treatment effect in all randomized patients and the genomic patient subset are prospectively specified,
we compare the statistical power between fixed and adaptive designs. We also compare the two types of
adaptive design. Results from simulation studies showed that adaptive design is more powerful than fixed de-
sign for those genomic or genetic biomarkers whose clinical utility is predictive of treatment effect. Pursuit
of adaptive design gains at least 20% to more than 30% genomic patient subset power when the genomic
biomarker status is readily usable at study initiation, in comparison to when it is explored using the first-
stage data of the same clinical trial. In exploratory studies, adaptive strategy provides wide flexibility in the
process of genomic or genetic biomarker development. In contrast, an adaptive design trial that employs
limited flexibility, and is an adequate and well-controlled investigation, has a greater power gain than 
a fixed design trial, in which the genomic biomarker is capable of predicting treatment effects that pertain
only to the prespecified genomic or genetic patient subset. [J Formos Med Assoc 2008;107(12 Suppl):
S19–S27]
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Conventional clinical trials are designed around
the primary objective and the primary efficacy
endpoint of the study. For instance, will the addi-
tion of the experimental treatment prolong sur-
vival when compared with standard care alone in
lung cancer patients? If the study concludes that
the new treatment is effective, the average treat-
ment effect, such as median survival in the above
example, and its standard error obtained from
the clinical trial, are used to provide a two-sided
95% confidence interval for the treatment effect,
which is applicable to all randomized patients
studied. This is often referred to as a one-size-
fits-all approach.
Pharmacogenomic or pharmacogenetic clinical
trials aim to identify effective therapeutics which
are to be facilitated by the genomic or genetic char-
acteristics of the patient (sub)population under in-
vestigation. To achieve this goal, the conventional
clinical trial design that addresses only the treat-
ment effect in all randomized patients has been
critically challenged. Study designs that allow the
clinical trial to address an additional study objec-
tive such as new treatment may only be effective in
patient subsets characterized by a genomic or ge-
netic profile. In this paper, we use the term genomic
collectively to also represent genetic, unless the
term genetic is specifically stated. We lay out the
utility of an adaptive strategy for genomic bio-
marker development, and discuss adaptive design
in pharmacogenomic clinical trials that build on
two study objectives. Is there a treatment effect in
all patients studied or is the effect only applicable
to a subset of patients who can be characterized by
the genomic biomarker1 or genomic classifier?2
When genomic materials or biological speci-
mens are a part of the data collection in clinical
trials, exploration of a genomic biomarker may
be pursued retrospectively from completed clinical
studies or from ongoing or prospectively planned
clinical trials. Here, we consider those biomarkers
whose presence can influence treatment outcome,
and whose status is or should have been known
prior to treatment initiation. In the following sec-
tion on Adaptive Strategy, I present a two-stage
adaptive strategy to explore a genomic biomarker.
In the section after that on Adaptive Design, I 
define the composite hypothesis and describe a
two-stage adaptive design in pharmacogenomic
or pharmacogenetic clinical trials. Adaptive de-
signs are compared with fixed designs when the
composite hypothesis is pursued.
Adaptive Strategy
There are many types of study design in pharma-
cogenomic or pharmacogenetic clinical trials.3 One
distinction among the possible designs is the ge-
nomic objective to investigate treatment effect in
a genomic patient (sub)population either in an
exploratory framework or in a statistical inferential
setting. The genomic patient population may be
the study population or a subpopulation of a
clinical trial. The genomic objective dictates the
study design. In addition, the availability of the
well-defined genomic biomarker and the accept-
ability of the diagnostic assay entail the appropri-
ateness of the study design in pharmacogenomic
or pharmacogenetic clinical trials.
Figure 1 contrasts the timing of genomic data
capture and the usage of genomic (composite)
biomarker information in pharmacogenomic or
pharmacogenetic clinical trials.
Development of genomic biomarkers
In clinical studies where the genomic objective is
exploratory, or clinical development of a genomic
(composite) biomarker is in progress, a two-stage
adaptive strategy can add to the design flexibility
efficiently. This is applicable to retrospective, 
ongoing, and prospective studies.
As shown in Figure 2, a two-stage adaptive strat-
egy for genomic biomarker development consists
of systematically training the genomic data for
exploration and discovery in stage 1, and prelim-
inarily validating the clinical utility of the trained
genomic biomarker in stage 2.4,5 There is abundant
statistical and bioinformatics literature for stage
1 and 2 development.2,6,7
Once a genomic biomarker is developed, ap-
proaches to validation such as leave-one-out, 
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k-folds cross-validation or bootstrap methods are
often used to assess the prediction accuracy. How-
ever, prediction error has been shown to be too
liberal using cross-validation approaches than
using independent validation.8 Validation per-
formed from a separate prospectively planned
study of the same patient population contains rig-
orous objective criteria for estimation of the pre-
diction error or prediction accuracy. During the
development process of a genomic (composite)
biomarker, studies that employ a two-stage adap-
tive strategy are considered exploratory, mostly to
generate a genomic hypothesis for later phase
study design consideration.
Preliminary clinical utility assessment
When a genomic biomarker is developed using
microarray technology or genotyping approach,
clear, commercially available diagnostics may be
required. Examples are AmpliChip9 and Mamma-
Print®.10 These diagnostics are used to classify 
patients into subsets. The clinical utility of the ge-
nomic biomarker may be prognostic of disease state
or drug effect, or predictive of treatment outcome
to be tested in adequate and well-controlled phar-
macogenomic or pharmacogenetic clinical trials.
For preliminary clinical utility assessment,
cross-validation performed in stage 2 provides es-
timated prediction accuracy, including sensitivity
and specificity of the genomic biomarker. The pos-
itive and negative predictive values of the diagnos-
tics can also be estimated if the pharmacogenomics
trial is a two-arm, placebo-controlled clinical trial
designed to explore patient subsets which are to be
ruled in for efficacy or ruled out because of seri-
ous adverse events. When previously completed
or ongoing trial data are used to develop genomic
biomarkers, the collected genomic biological spec-
imen may be used to assess the preliminary clinical
utility of an experimental diagnostics.
The major statistical issue here is the data
quality of the stored genomic samples. Some ge-
nomic samples yield unknown genomic biomarker
status, which is a type of missing data problem.
Baseline demographics,
disease characteristics
background medication
Clinical outcomes:
primary, secondary efficacy,
safety endpoints
Baseline genomic or genetic samples
(e.g. tissue, biospecimen, blood, PBMC)
Pharmacogenomic or pharmacogenetic 
randomized controlled clinical trial
No 
Is an established genomic (composite)
biomarker classifier or a genomic or genetic
diagnostic assay available at study baseline?
Stratified randomization is an option
in addition to a prespecified statistical
analysis plan
Yes 
Prospective statistical analysis plan
to also study therapeutic effect in
genomic or genetic subgroup(s)
Conventional clinical trial
Figure 1. Diagram of timing of genomic data capture and usage of genomic (composite) biomarker information in pharma-
cogenomic or pharmacogenetic clinical trials. The dashed line represents conventional randomized controlled clinical trial. The
solid lines with arrows represent the chronologic timeline of a genomic drug trial. PBMC=peripheral blood mononuclear cells.
Completed trials
Ongoing trials
Prospective trials 
Stage 1
Exploration/discovery
(training dataset) 
Stage 2
Preliminary validation
(test dataset) 
• Prespecify the statistical methodologies to systemati-
 cally explore and develop a genomic or genetic
 biomarker classifier, e.g. using 60% of accrued patients
 for stage 1 exploration/discovery—the training set
• Cross-validate the potential classifier effect using the
 remaining data (to be) collected in stage 2
Figure 2. Development of a genomic (composite) biomarker
two-stage adaptive/flexible strategy for exploration.
S.J. Wang
S22 J Formos Med Assoc | 2008 • Vol 107 • No 12 Suppl
A compounding issue is that the genomic objec-
tive is not a primary objective of these trials. As a
consequence, only optional consent is needed for
the exploratory genomic objective. The genomic
samples so collected are convenience samples of a
double-blind randomized controlled trial. These
characteristics can easily be lost for a randomized
comparison of a treatment effect within a genomic
subset. The clinical event following treatment 
intervention serves as the clinical truth, and the
diagnostic assay using biological specimens to
classify patients serves as the test result. Prevalence
of positive genomic biomarkers can be estimated
using only data from placebo patients.
Adaptive Design
An adaptive design consists of three components:
(1) a prospectively planned modification of one
or more specified design elements; (2) a modifi-
cation performed in a specified manner based on
an interim analysis of data from subjects in the
study; and (3) interim analyses at prespecified
time points, performed either fully blinded or
unblinded, and with or without a formal statistical
hypothesis test.
Genomic biomarker or diagnostic assay
available prior to treatment assignment
Depending on the genomic study objective, there
are several design options.3 Ideally, there should be
a developed genomic biomarker and an accept-
able diagnostic assay available at study initiation
to classify patients’ biomarker status (Figures 1
and 2). In such cases, a two-stage adaptive de-
signed pharmacogenomic or pharmacogenetic
trial can be devised. The basic setup considered
in this paper is that, at trial initiation, all patients
are randomized, preferably stratifying by their
biomarker status to ensure randomization balance
within each genomic patient subset. Statistical
inference of a treatment effect relative to its com-
parator is formally assessed in all patients ran-
domized and in the patient subset defined by the
presence of the genomic biomarker. We refer to
this as the composite hypothesis. It is worthwhile
noting that assessment of differential treatment
effects between biomarker-positive and -negative
patients is only of secondary interest, which is
also known as the interaction hypothesis.3
The composite hypothesis is specified a priori.
The adaptive features at the end of stage 1 interim
analysis may be to conduct: (1) a futility or safety
assessment of the patient subset with absence of
the genomic biomarker; (2) an interim predictive
power assessment of treatment effect in the patient
subset with the genomic biomarker; (3) an increase
in total sample size; and (4) an increase in sam-
ple size in the to-be-enriched genomic biomarker
patient subset. One can also build in a formal in-
terim analysis for early efficacy decision as in adap-
tive group sequential design. However, we generally
discourage such adaptation, especially if an interim
analysis is performed early when the sample size
is small.
When the composite hypothesis is the primary
study objective, a study where no design element
is adapted is a fixed design, within which a pre-
specified multiplicity adjustment method is in
place, e.g. Hochberg procedure. Compared with
the fixed design, the attractive utility of adaptive
design in terms of gaining the study power to de-
tect a treatment effect in the genomic subset is
when the genomic biomarker is predictive of treat-
ment effect, viz. those solid subset power curves
for 1= (>0, g+=0.4, g−=0) denoted by AD-1
(adaptive design 1) and 2 = ( = 0, g + = 0.4,
g− < 0) denoted by AD-2 versus those dashed
subset power curves for FD-1 (fixed design 1) and
FD-2 depicted in Figure 3. With 1 = ( > 0, g + =
0.4, g−=0), the true standardized effect size is 0.4
in the genomic-biomarker-positive subset and no
treatment effect in the biomarker-negative subset
(g− = 0). Similarly, with 2 = ( = 0, g + = 0.4,
g−< 0), in the extreme situation, the null overall
treatment effect is the result of the treatment effect
being offset because it benefits one type of geno-
mically defined patient subset, but is futile to the
complementary genomic subset. In contrast, when
the genomic biomarker is prognostic-predictive of
treatment effect, viz. there appears to be differential
Biomarker-facilitated patient adaptation in pharmacogenomic clinical trials
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treatment effects between biomarker-positive
and -negative patient subsets with treatment dif-
ferences on an order of magnitude. In such cases,
there is essentially no genomic subset power gain
with the adaptive design approach (see AD-3 
versus FD-3 in Figure 3).11
Genomic materials collected, but biomarker
status not known prior to treatment
assignment
When exploration of clinical utility and develop-
ment of a genomic biomarker is prospectively
planned using stage 1 data, there is clearly no es-
tablished genomic biomarker or acceptable diag-
nostic assay at study initiation. Let us assume that
one is willing to accept that emerging scientific
findings external to the clinical trial independently
validate the prediction accuracy of a genomic bio-
marker preliminarily developed within the trial
and before its completion. In this case, a two-stage
adaptive design may be pursued.12 The adaptive
signature design by Freidlin and Simon12 uses in-
terim stage 1 data to identify existence of a sensitive
genomic patient subset.
Wang et al13 studied the performance charac-
teristics of a two-stage adaptive design when the
genomic biomarker was readily available at study
baseline versus when it was only available at the
end of stage 1 interim analysis. Using a one-sided
equal α-split of 0.0125 for each of the two prospec-
tively specified hypotheses,12 simulation studies13
have shown that, when the genomic biomarker
is predictive of clinical outcome, an adaptive design
with available genomic biomarker status at study
baseline yields at least 20% to more than 30%
subset power improvement, compared to adaptive
design without available genomic biomarker status
at trial initiation (Figure 4).13 This is roughly a
15–30% subset power gain for prognostic utility
(Figure 5A in Wang et al,13 which is reproduced
as Figure 5 in this article).
Discussion
In previously completed controlled clinical trials
where genomic biological specimens were col-
lected prior to trial initiation, we rationalized the
feasibility of genomic biomarker exploration using
a two-stage adaptive strategy. The exploration could
be driven by the completed studies succeeding in
demonstrating a treatment effect. However, re-
defining a responsive genomic patient subpop-
ulation may become necessary because of the
changing definition of disease or syndrome in
the clinical community, or de-selecting an unsafe
genomic patient subpopulation may become ethi-
cally plausible because of irreversible drug-related
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Figure 3. Power comparison for g+ with the Hochberg method (1= (, 0.4, 0); 2= (0, 0.4, g−<0); 3= (0.2, 0.4, g−)).
, g+ and g− are the standardized effect sizes for all randomized patients, the genomic biomarker positive patients,
and the genomic biomarker negative patients. Sample size ratio is the ratio of sample size in genomic biomarker positive
patients over all randomized patients. FD = fixed design; AD = adaptive design. 1 and 2 refer to the genomic biomarker
that is predictive of treatment effect, 3 refers to prognostic prediction of treatment effect.
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adverse events.14 The exploration could also be
driven by studies failing to statistically demon-
strate treatment effects based on all the patients
studied.
Development of a genomic biomarker is ex-
ploratory in its process. The critical issues are not
necessarily the multiplicity that occurs in the se-
lection of gene features or prediction models, or
the strong control of falsely identifying baseline
genomic biomarkers for patient classification. The
main clinical question is whether there is a useful
clinical utility of the developed genomic biomarker
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Figure 5. Power comparison for g+ under adaptive designs with the standardized effect sizes for all randomized patients,
the genomic biomarker positive patients, and the genomic biomarker negative patients: =0.2, g+=0.4, g− (a function
of , g+, and the sample size ratio). Sample size ratio is the ratio of sample size in genomic biomarker positive patients
over all randomized patients. AD = adaptive design with alpha allocation by Wang et al;13 FS = adaptive design by Freidlin
and Simon;12 0.0125 refers to a one-sided 1.25% type I error rate (equal allocation) for testing H0: g+ = 0 and H0: = 0
each; 0.005 refers to a one-sided 0.5% type I error rate for testing H0: g+ = 0 and the remaining one-sided 2% type I
error rate for testing H0: = 0; Hochberg refers to testing the two hypotheses following the adaptive design using the
Hochberg procedure by Wang et al.13
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Figure 4. Power comparison for g+ under adaptive designs with the standardized effect sizes for all randomized patients,
the genomic biomarker positive patients, and the genomic biomarker negative patients:  (a function of g+, g− and
the sample size ratio), g+=0.4, g−=0. Sample size ratio is the ratio of sample size in genomic biomarker positive patients
over all randomized patients. AD = adaptive design with alpha allocation by Wang et al;13 FS = adaptive design by Freidlin
and Simon;12 0.0125 refers to a one-sided 1.25% type I error rate (equal allocation) for testing H0: g+ = 0 and H0: = 0
each; 0.005 refers to a one-sided 0.5% type I error rate for testing H0: g+ = 0 and the remaining one-sided 2% type I
error rate for testing H0: = 0; Hochberg refers to testing the two hypotheses following the adaptive design using the
Hochberg procedure by Wang et al.13
or an added clinical utility over existing baseline
clinical indicators. Therefore, a two-stage adaptive
strategy provides flexibility when it comes to in-
vestigating several plausible statistical methods,
selecting individual genes/single nucleotide poly-
morphisms and several plausible prediction algo-
rithms and developing a genomic (composite)
biomarker. Through an iterative process searching
for a genomic biomarker, ultimately, the genomic
biomarker that best informs the clinical utility of
drug response or treatment effect will be brought
forward for genomic inference of a treatment effect
in the drug development process.
It has been argued that DNA is highly stable
physically and biologically. Thus, DNA genotyping
data will be the same regardless of when the DNA
samples are acquired, if these samples are properly
stored and maintained. Consequently, if the geno-
typing laboratory is blinded to the clinical outcome
data and the treatment assignment, some have
argued that designing a prospective pharmacoge-
nomic study to test the clinical composite hypoth-
esis using available unblinded clinical data is
possible from previously completed drug trials,
assuming that the study sample size is sufficiently
powered for the genomic hypothesis. This is known
as a prospective/retrospective study design.14
The scientific validity of a prospective/retro-
spective study design depends on the intended
clinical utility of the established genomic bio-
marker and an acceptable diagnostic assay for
patient classification.14 The prospectiveness of the
prospective/retrospective study design in terms of
prespecified modification of design elements in
a two-stage adaptive design trial might be accept-
able using previous successfully completed clini-
cal trials for the “new” composite hypothesis, but
not in failed trials that no longer have an objec-
tive type I error definition and which should be
considered hypothesis generation at best.
However, the scientific validity of the prospec-
tive/retrospective study design has been a subject
of controversy. It is challenging when the intended
clinical utility is “predictive of drug effect at
group level”, and the two-stage adaptive design13
gives a large power gain over the conventional
one-size-fits-all design or fixed design with pre-
specified multiplicity adjustment of the composite
hypothesis. One cannot rule out the possibility of
iterative discovery from retrospective sources, such
as previously completed clinical trials, being used
in hypothesis generation. The multiplicity that re-
sults from iterative discovery may be of concern.
The validity of the two-stage adaptive design can
also be challenged because of the unavailability of
a homegrown assay or an unacceptable diagnostic
assay that lacks performance characteristics ex-
pressed by sensitivity, specificity, accuracy, positive
predictive value, negative predictive value, and re-
ceiver operating characteristic curve. The funda-
mental issues are the completeness of ascertaining
biological specimens in all randomized patients,
whether the specimen quality allows accurate clas-
sification of all randomized patients, the amount
of missing data on genomic biomarker classifica-
tion status caused by specimen quality, and the
convenience genomic samples due to optional bio-
specimen collection. Thus, the issue of the level of
scientific rigor and the various issues of bias of
prospective/retrospective investigations that arise
from the design, analysis, conduct and interpreta-
tion of a completed clinical trial cannot be ignored.
When the specificity and sensitivity add up to
100% or positive and negative predictive values
add up to 100%, it is likely that a genomic patient
subset will be randomly selected, which shows
no clinical utility of the genomic biomarker or
the diagnostic assay. When the diagnostic perfor-
mances deviate from random classification, there
are always trade-offs between sensitivity and speci-
ficity, and similarly, between positive and negative
predictive values. In general, high sensitivity is
favored for early, less expensive, noninvasive tests,
and high specificity is favored for later stages
when more expensive and invasive tests are per-
formed. Alternatively, predictive value may be
used for diagnostic performance. The trade-offs
for the predictive value of a genomic biomarker
may be more serious for its predictive clinical utility
than for its prognostic clinical utility. In the case
of MammaPrint®, which has been approved for
its prognostic clinical utility, a reasonably high
Biomarker-facilitated patient adaptation in pharmacogenomic clinical trials
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negative predictive value may be acceptable for
detecting no metastatic breast cancer within 5 years.
For rare clinical events, a high negative predictive
value is easily achievable and the positive predictive
value is naturally low, e.g. MammaPrint® was ap-
proved on the basis of a high negative predictive
value of 0.95 (95% confidence interval of 0.91–
0.99), but a very low positive predictive value (0.22,
with 95% confidence interval of 0.16–0.28) for
metastatic breast cancer within 5 years.15
Studies with the genomic objective that a ge-
nomic biomarker is predictive of treatment effect
should only be prospectively planned and de-
signed, and should not be a secondary attempt
from within a previously completed clinical trial.
This is because one predicts a future event, and not
a future event in the past tense. In addition, the de-
sign of the original trials might add exploratory ge-
nomic objectives at best when there was a lack of
emerging scientific evidence. Thus, the original trial
would be unlikely to accommodate the DNA anal-
ysis in its formal primary study objective or its key
secondary objective, from which these completed
studies cannot possibly make themselves prospec-
tive for collection of legitimate future events.
Genomic technology4,5,9,10 promises a revolu-
tion in therapeutic discovery and clinical investi-
gation that aims to provide more precise diagnosis
and prognosis, a better understanding of drug 
action, and the ability to better define therapeutic
strategies. Pharmacogenomic clinical trials provide
the link between target agent and target (sub)pop-
ulation, by way of enriching genomic patient pop-
ulation or adaptively enriching genomic patient
subpopulation. To achieve these goals, one can
think ahead in early phase drug development to
seek an influential genomic biomarker that sup-
ports or discovers the drug mechanism of action
or identifies drug targets. Adaptive approaches
are feasible. The successful treatment of individual
patients based on a predictive genomic biomarker
that provides added clinical value and clinical
utility can be viewed as a substantial first step 
toward personalized medicine.
We have introduced and discussed two-
stage adaptive strategy for genomic biomarker
development and two-stage adaptive design to pre-
identify genomic or genetically prone patients who
are expected to respond (better) to therapy, in the
sense of treatment risk/benefit balance, than pa-
tients without these genomic or genetic character-
istics in pharmacogenomic and pharmacogenetic
clinical trials.
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